SMARCA4欠乏性NSCLCにおけるフェロプトーシス感受性を高めるためにALDH16A1媒介のチオレドキシン分解を標的とする
Guoshu Bi1, Jiaqi Liang1, Yunyi Bian1
1Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Nature communications
|September 2, 2025
まとめ
肺がんにおけるSMARCA4欠乏は,ALDH16A1とチオレドキシン (TXN) を調節することによって,細胞をフェロプトーシスに敏感にします. ALDH16A1の回復またはTXNの抑制は,フェロプトーシス抵抗性がんの化学療法/免疫療法の有効性を高めます.
科学分野:
- 生物化学
- 分子生物学
- 腫瘍学
背景:
- 制御された細胞死経路であるフェロプトーシスは 癌治療の有望な標的です
- SMARCA4のような腫瘍抑制剤がフェロプトーシスとがん治療に対する抵抗性における役割は完全に理解されていません.
研究 の 目的:
- SMARCA4欠乏が非小細胞肺がん (NSCLC) のフェロプトーシスに影響するメカニズムを調査する.
- SMARCA4欠乏性NSCLCにおける治療抵抗性を克服するための治療戦略を特定する.
主な方法:
- フェロプトーシスの調節におけるSMARCA4の役割の分析.
- SMARCA4,ALDH16A1,およびチオレドキシン (TXN) の相互作用を調査する.
- NSCLCモデルにおけるALDH16A1またはTXNを調節する治療の可能性を評価する.
主要な成果:
- SMARCA4欠乏症は,ALDH16A1を上調することによって,NSCLC細胞をフェロプトーシスに敏感にする.
- ALDH16A1は,抗フェロプト性タンパク質TXNを標的とし,その機能を阻害する.
- ALDH16A1の回復またはTXNの抑制は,フェロプトーシス依存の方法で化学療法/免疫療法の有効性を高めます.
結論:
- 新しいSMARCA4-ALDH16A1-TXN制御軸がフェロプトーシスを制御する.
- この軸をターゲットにすることで,SMARCA4欠乏性NSCLCの治療戦略を提供し,化学療法/免疫療法に対する抵抗を克服する可能性がある.
さらに関連する動画
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
18.8K
09:21Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts
Published on: February 23, 2024
1.0K
関連する概念動画
Electron Transport Chain: Complex I and II
15.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.0K
Necrosis
4.8K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.8K
Lysosomal Hydrolases
3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
Export of Misfolded Proteins out of the ER
3.9K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
3.9K
